XTAMPZA: cost and payments to doctors
What Medicare Part D paid pharmacies for XTAMPZA, and the payments that named it as the associated drug or biological under the Sunshine Act for program years 2019–2025.
Part D cost for XTAMPZA formulations
Medicare reports XTAMPZA under its specific formulations, which are priced separately.
- xtampza er$628per 30-day fill · 317,492 claims · Oxycodone Myristate
Paid to pharmacies by Part D plans and patients — not your cost, and not paid to the prescriber. Is this wrong?
Was your doctor paid by Collegium Pharmaceutical, Inc.?
Collegium Pharmaceutical, Inc. reported the most payments naming XTAMPZA. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $4.2M
- Providers
- 12,826
- Transactions
- 115,875
- Average per transaction
- $36
The per-transaction average — $36 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 12,826 providers the average total is $326, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Collegium Pharmaceutical, Inc. | $4,179,196 | 100.0% |
Other products from Collegium Pharmaceutical, Inc.
The company that reported the most payments naming XTAMPZA also reports against these.
- BELBUCA$3,350,195
- Nucynta$2,346,745
- JORNAY PM$1,520,389
- ELYXYB - CELECOXIB$79,630
- Xtampza ER$18,117
- Nucynta ER$3,382
- NucyntaER$1,049
- Symproic$280